Pharmaceutical Technology11m
Risk adjusted net present value: What is the current valuation of Roche’s RG-6641?
RG-6641 is a synthetic peptide commercialized by Roche, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ...
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of Cogent Biosciences’s Bezuclastinib?
Bezuclastinib is a small molecule commercialized by Cogent Biosciences, with a leading Phase III program in Gastrointestinal Stromal Tumor (GIST).
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of Xencor’s Plamotamab?
Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase I program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL).
Pharmaceutical Technology29m
Risk adjusted net present value: What is the current valuation of Ono Pharmaceutical’s Vimseltinib?
Vimseltinib is a small molecule commercialized by Ono Pharmaceutical, with a leading Pre-Registration program in Tenosynovial Giant Cell Tumor.
Pharmaceutical Technology29m
Risk adjusted net present value: What is the current valuation of Immunome’s AL-102?
AL-102 is a small molecule commercialized by Immunome, with a leading Phase I program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma.
Pharmaceutical Technology40m
Risk adjusted net present value: What is the current valuation of AC Immune’s ACI-24?
ACI-24 is a vaccine commercialized by AC Immune, with a leading Phase II program in Alzheimer’s Disease. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 ...
Pharmaceutical Technology34m
Risk adjusted net present value: What is the current valuation of Oryzon Genomics’s Iadademstat?
Iadademstat is a small molecule commercialized by Oryzon Genomics, with a leading Phase II program in Neuroendocrine Carcinoma.
Pharmaceutical Technology38m
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s Adakitug?
Adakitug is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Solid Tumor.
Pharmaceutical Technology40m
Risk adjusted net present value: What is the current valuation of Jasper Therapeutics’s Briquilimab?
Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID).